The four new SOLiD machines, which will operate in DNAVision's Brussels facility, will add to the company's existing fleet of two Illumina HiSeq 2000 and one Roche 454 GS FLX.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.
The new platform will add to the firm's existing next-gen sequencing services on the Illumina HiSeq 2000, Illumina GAIIx, and Roche 454 GS FLX.
DNAVision CEO Jean-Pol Detiffe said this week that the company will use the HiScanSQ for its pharmaceutical and medical research customers' ongoing genome-wide association projects.
The company expects to receive the instrument before the end of June and will install it at its facility in Gosselies, Belgium.
The HiSeq 2000 joins DNAVision's other next-gen sequencing platforms that are used in its genomics services offerings.
Klaus Lindpainter is the new VP of R&D and CSO at Strategic Diagnostics; Intrexon appoints Thomas Goralski as senior VP; WARF loses director of licensing Craig Christianson, and more.
Randox Laboratories, Ocimum Biosolutions, DNAVision, Illumina
Illumina certified DNAVision to provide genotyping services using Illumina's Infinium platform.
The Belgian companies will offer the microarray analysis platform to biotech and pharma firms.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.